Published in Gene Therapy Weekly, May 20th, 1996
Numerous institutions have investigated suicide gene therapy using herpes simplex thymidine kinase gene transduction followed by ganciclovir treatment. Mark Barnes and colleagues from the University of Alabama took a different approach and explored the ability of a single chain antibody (sFv) to down regulate an oncogene thereby rendering it susceptible to subsequent chemotherapy.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.